Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibition in Renal Transplant Patients
NCT04665830Phase 3Completed
- Sponsor
- Hamid Al-Essa Organ Transplant Center
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular disease (CVD) comparing Evolocumab + Statin with Placebo + Statin (2 arms). Primary endpoint: Major cardiovascular events at 24 months. Started May 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04665830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665830.